Side-by-side · Research reference
TeriparatidevsTirzepatide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AFDA-ApprovedHUMAN-REVIEWED10/62 cited
BFDA-ApprovedFlagship14/45 cited
Teriparatide
PTH (1-34) Fragment · FDA-Approved
SQ · Thigh/Abdomen · Once Daily
Tirzepatide
GIP+GLP-1 Dual Agonist · FDA-Approved
SQ · Abdomen / thigh / arm · Once weekly
01Mechanism of Action
Parameter
Teriparatide
Tirzepatide
Primary target
Parathyroid hormone 1 receptor (PTH1R) on osteoblastsXue 2026
GIP receptor (GIPR) + GLP-1 receptor (GLP-1R)Frias 2018
Pathway
PTH1R activation → cAMP/PKA signaling → osteoblast differentiation and activity
Dual GIPR/GLP-1R agonism → ↑insulin (glucose-dependent), ↓glucagon, ↓gastric emptying, ↓appetite, ↑energy expenditure (via GIP component)Jastreboff 2022Frias 2018
Downstream effect
Stimulates osteoblast formation and bone matrix deposition; increases bone mineral density at trabecular and cortical sites
Profound glycemic improvement and weight reduction; cardiometabolic benefitsJastreboff 2022
Feedback intact?
Yes — intermittent dosing preserves anabolic effect; continuous exposure causes catabolic bone resorption
Glucose-dependent insulin release preserves physiological feedback
Origin
Recombinant 34-amino-acid N-terminal fragment of 84-amino-acid human PTH
39-AA peptide with C-20 fatty-acid acylation. Single molecule with balanced GIP + GLP-1 affinityFrias 2018
Antibody development
—
—
02Dosage Protocols
Parameter
Teriparatide
Tirzepatide
Standard dose (osteoporosis)
20 mcg / day
FDA-approved regimen for severe osteoporosis.
—
Frequency
Once daily
Intermittent administration preserves anabolic effect.
—
Maximum duration
24 months lifetime
Anabolic effect wanes after 12-18 months; FDA recommends max 2-year cumulative exposure.
—
Hypoparathyroidism dose
20 mcg / day
Used off-label for chronic hypoparathyroidism.
—
Evidence basis
RCT / FDA-approved
FDA-approved · Phase 3 RCTs (SURMOUNT, SURPASS)Jastreboff 2022ZEPBOUND (tirzepatide) injecti 2023
Pelvic fragility fractures
20 mcg / day × 8-12 weeks
Accelerates fracture healing; reduces time to union.Crooks 2026
—
Route
Subcutaneous (thigh or abdomen)
—
Timing
Morning or evening (flexible)
Once weekly, any time of day
Storage
Refrigerate 2-8 °C; pen device stable at room temp for 28 days after first use
—
Pharmacogenetics
ALDH2 polymorphisms may influence BMD responseObara 2026
ALDH2*2 variant carriers show altered PTH receptor expression.Obara 2026
—
Standard dose (weight)
—
5, 10, or 15 mg / week (titrated)ZEPBOUND (tirzepatide) injecti 2023Jastreboff 2022
Titration schedule
—
2.5 mg → +2.5 mg every 4 weeks → 15 mg max
Slower titration mitigates GI side effects.
Duration
—
Indefinite for chronic indication
Reconstitution
—
Pre-filled commercial pen. Research vial: bacteriostatic water per label.
03Metabolic / Fat Loss Evidence
Parameter
Teriparatide
Tirzepatide
Fat loss application
None — teriparatide is a bone anabolic agent without direct lipolytic activity
—
04Side Effects & Safety
Parameter
Teriparatide
Tirzepatide
Hypercalcemia
Transient serum calcium elevation 4-6 hours post-injection
Monitor serum calcium; usually asymptomatic.
—
Orthostatic hypotension
Dizziness, lightheadedness within hours of injection
—
Nausea
Common, usually mild and transient
—
Leg cramps / Arthralgia
Musculoskeletal pain reported in clinical trials
—
Hypercalciuria
Increased urinary calcium excretion; monitor for nephrolithiasis risk
—
Osteosarcoma (black box warning)
Rat studies showed dose-dependent osteosarcoma; not observed in humans to date; contraindicated in Paget's disease, skeletal malignancy, prior radiation
—
Injection site reaction
Erythema, bruising, pain (uncommon)
Mild erythema, pruritus
Thyroid C-cell tumours
—
Boxed warning — contraindicated in MEN2 / MTC historyZEPBOUND (tirzepatide) injecti 2023
Hypoglycemia
—
Low as monotherapy; risk with sulfonylureas / insulin
Gallbladder events
—
Increased cholelithiasis
Pregnancy / OB
—
Contraindicated
Diabetic retinopathy
—
Rapid glycemic improvement may transiently worsen
Absolute Contraindications
Teriparatide
- ·Paget's disease of bone (increased baseline osteosarcoma risk)
- ·Unexplained elevated alkaline phosphatase
- ·Prior skeletal radiation therapy
- ·Skeletal malignancies or bone metastases
- ·Hypercalcemic disorders (primary hyperparathyroidism)
- ·Pregnancy / lactation
Tirzepatide
- ·MTC personal or family history; MEN2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to tirzepatide
Relative Contraindications
Teriparatide
- ·Active or recent nephrolithiasis
- ·Severe renal impairment (CKD G4-G5)
- ·Hypercalciuria without adequate monitoring
Tirzepatide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Diabetic retinopathy
05Administration Protocol
Parameter
Teriparatide
Tirzepatide
1. Device preparation
Teriparatide is supplied in pre-filled pen injectors (Forteo pen). Store refrigerated at 2-8 °C until first use. After first injection, pen may be kept at room temperature for up to 28 days. Do not freeze.
Commercial: pre-filled pen / vial. Research lyophilised: bacteriostatic water per label.
2. Injection site
Subcutaneous injection into thigh or lower abdomen. Rotate sites daily to avoid lipodystrophy. Avoid areas with scars, bruises, or active skin conditions.
SQ — abdomen, thigh, or upper arm. Rotate weekly.
3. Timing
Once daily, at approximately the same time each day. Morning or evening administration is acceptable. Take while sitting or lying down to minimize orthostatic hypotension risk.
Once weekly, same day. Day change allowed if ≥3 days separate doses.
4. Injection technique
Clean injection site with alcohol swab. Pinch skin, insert needle at 90° angle, and inject full dose (20 mcg). Hold for 5 seconds before withdrawing needle. Do not rub injection site.
Refrigerate 2–8 °C unopened. Room temp ≤30 °C up to 21 days after first use.
5. Monitoring
Baseline and periodic monitoring of serum calcium, urinary calcium, serum PTH (if hypoparathyroidism), and bone mineral density (DXA scan). Monitor for hypercalcemia 4-6 hours post-dose if symptomatic.
Pen-supplied. Research vial: 27–31G insulin syringe.
6. Calcium and vitamin D supplementation
Ensure adequate calcium (1000-1200 mg/day) and vitamin D (800-1000 IU/day) intake unless contraindicated by hypercalcemia or hypercalciuria.
—